IJBPAS, November, 2022, 11(11): 5080-5105

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

SYSTEMIC ROLES OF PEROXISOME PROLIFERATED ACTIVATED RECEPTOR'S IN NON ALCOHOLIC FATTY LIVER DISEASE: AN OVERVIEW

PADALEESWARAN T[1], SUMITHRA M[2*] AND CHITRA V[3]

1: Department of Pharmacology, Student, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, India - 603203

2: Department of Pharmacology, Associate Professor, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, India – 603203

3: Department of Pharmacology, Head Of The Department, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, India - 603203

***Corresponding Author: Dr. Sumithra M: E Mail: sumi26379@gmail.com**

Received 27th Dec. 2021; Revised 25th Jan. 2022; Accepted 28th Feb. 2022; Available online 1st Nov. 2022

https://doi.org/10.31032/IJBPAS/2022/11.11.6550

ABSTRACT

The Non-alcoholic liver fatty disease (NAFLD) impacts many developed countries on up to one-third of the population, and it is a growing outbreak. Non-alcoholic steatohepatitis (NASH) can further results in cirrhosis, between 10% to 30% of NAFLD patients. Many risk factors in NAFLD development were supported because most NAFLD's pathophysiology has some kind of metabolic disarrangement and it can be resistant to insulin. Patients with NAFLD are more likely to experience both hepatic and cardiovascular mortality. The standard for definite diagnosis is Liver Biopsy; however, the development of advanced, non-invasive imagery, biochemical and genetic tests will certainly offer future clinicians much information and opportunities for enhanced intelligence and targeted treatment on pathogenesis. Their management largely depends on the disease stage and emphasizes that careful stratification of the risk is essential. In this review, we described the functions of NAFLD and the receptors involved in the differential diagnosis, which helps to understand this disease and manage NAFLD patients more effectively.

Keywords: Liver biopsy, NASH, PPAR- α,PPAR- β / δ. PPAR- γ

INTRODUCTION

The liver is one of the body's biggest organs and is responsible for energy and xenobiotic metabolism. Although nuclear receptors have been shown to control xenobiotic metabolism, their specific functions includes the metabolism of glucose and lipids that have been just lately discovered.[1] Nuclear receptors are therefore not required for proper liver function. Metabolic disturbances can be the cause and an effect on liver disease. Fatty liver disease is a physiological diseases with pathological spectrum ranging from hepatocyte fat excess also called steatosis to the increase of Inflammatory (steatohepatitis) and scarring coexist that leads to cirrhosis and, potentially, hepatocellular carcinoma.[2] Exposure to external substances is the most common cause of fatty liver disease. While the disease processes may change depending on the kind of exposure, the resultant liver pathology is not distinguishable.[3] As a result, fatty liver disorders are labelled according to their cause. Alcohol (alcoholic liver disease) (ALD/ASH); and Diet-induced obesity (NAFLD/NASH) and other frequent causes were recently investigated. Exposure to toxicant-associated fatty liver disease (TAFLD/TASH) and chemotherapy-associated steatohepatitis (CASH).This can be the most causable metabolic liver disease across the globe, which ranges from 10 to 45 percent in various nations.

In actuality, NAFLD encompasses a wide range of hepatic abnormalities that may be seen on histological slides of the liver, ranging from simple intrahepatic fat accumulation (steatosis or nonalcoholic fatty liver, NAFL) to varying range of necrotic inflammation (nonalcoholic steatohepatitis,).[4] Over a 15-year period, simple steatosis (i.e., NAFL) seldom develops to advanced illness, whereas NASH eventually leads to fibrosis and cirrhosis, as well as the development of hcc in about 20% of individuals.[5] However NAFLD patients at high risk of severe liver disease, such as steatohepatitis or cirrhosis, should have this test performed.[6] Appreciating the NAFLD pathological terminology can be crucial not only for pathologists in their everyday diagnostic work, Hepatologists, on the other hand, can use it to communicate with pathologists and also to the patients[7] Steatosis and even steatohepatitis are common in viral hepatitis C, drug-induced liver damage (e.g. Nolvodex-D, tamoxifen, steroids), Wilson disease, and a variety of metabolic liver disorders. This can give the quick attorney's reference to pathologic differences that cause NAFLD, as well as some practical advice for general pathologists.[8]

Non-alcoholic fatty liver disease (NAFLD) has become the urgent worldwide health concern due to a pandemic of overnutrition and its associated metabolic hazards, such as there is a high prevalence of central adiposity as well as hyperglycaemia, dyslipidaemia[9] NAFLD can be the prevalent hepatic metabolism worldwide, with prevalence rates ranging from 10 to 45 percent in various nations. Under the impact of a "westernised" sedentary lifestyle, the prevalence of NAFLD does not differ considerably between Western and the Asian nations.[10] NAFLD is hepatitis, liver cirrhosis, and heart disease are the leading causes of liver transplant, with substantial morbidity and mortality.[11] It's critical to have a correct diagnosis of NAFLD so that patients may be managed properly and quickly to reduce morbidity and death. NAFLD encompasses a wide range of diseases, including steatosis, non-alcoholic steatohepatitis (NASH), and cirrhosis.[12] To measure that which liver steatosis and steatohepatitis are present in patients with NAFLD several non-invasive diagnostics based on clinical, laboratory, and radiographic examinations have been established. Despite the fact that liver biopsy is an invasive procedure with a Individuals with NAFLD at high risk of steatohepatitis and advanced fibrosis (bridging fibrosis and cirrhosis) should undergo this test, which is the best model for evaluating hepatic pathology in patients with NAFLD. Understanding NAFLD pathological terminology is crucial isn't only for pathologists in their everyday diagnostic work, it is also for hepatologists in their ability to communicate with pathologists and to the patients. Steatosis and even steatohepatitis are common in Drug-induced liver problems from viral hcv Infection (e.g.Nolvodex-D, Soltamox, steroids), and a variety of metabolic liver disorders.[13]This gives quick summary of the pathological alterations that cause NAFLD, as well as some practical advice for general pathologists.[14]

Classification of steatosis based on inflammation

NAFLD's key pathological condition is hepatic steatosis (fatty change), which can be defined as the cytoplasmic body fat build up, Initially triglycerides, in hepatocytes. According to research using lipid content measurement and imaging, a cut-off of 5% is utilised to distinguish between normal and pathological steatosis.[15] The Hepatic fatty change in morphologic forms are macrovesicular and microvesicular steatosis. The classic definition of macrovesicular steatosis is a hepatocyte where the nuclei is being pushed to the peripheral by a fatty droplet.[16] Hepatocytes with many tiny to medium-sized fat droplets in close proximity to hepatocytes with a single giant

fat droplet are not uncommon. The fusing of several small to medium-sized fat droplets is thought to generate a single giant fat droplet.[17] As a result, the term "macrovesicular steatosis" should be expanded to include hepatocytes containing small to medium-sized fat droplets. Microvesicular steatosis, on the other hand, is characterised by the formation of much smaller homogeneous minute fat droplets that are scattered throughout the hepatocytes.[18]The nucleus of a hepatocyte with microvesicular steatosis is centrally positioned, and the cytoplasm is foamyDue to the underlying mitochondrial malfunction and fatty acid oxidation deficiency, diffuse microvesicular steatosis is commonly seen in potentially life-threatening clinical situations such as hepatic encephalopathy and acute liver failure. Diffuse microvesicular steatosis is characterised by acute alcoholic foamy degeneration, Reye syndrome, and early liver failure of gestation. Although diffusion of the microvesicular steatosis is not the clinical characteristic of NAFLD, focused microvesicular steatosis was observed in about 10% of NAFLD patients' liver biopsies. In the context of conventional macrovesicular steatosis, the existence of focused microvesicular steatosis in NAFLD has been in association with Higher levels of steatosis, hepatic enlargement, activation, and clinical signs indicate a more severe illness.[19]

In a liver biopsy, the degree and location of steatosis should be documented in the pathology report. For evaluation, histological examination by using low-power [i.e., 10x and generally 4x objective] is ample. Higher-resolution steatosis evaluations can be avoided since the degree of steatosis is overestimated. The severity of fatty change is defined semi-quantitatively into three levels: mild [5% to33%], moderate (>33% to 66%), and severe (>66 percent). Ballooning of hepatocytes, Mallory-Denk bodies, and portal /progressive fibrosis are not associated with the degree of steatosis, which is linked to lobular inflammation and centrizonal fibrosis.[20] Unless such steatosis is too moderate or the biopsy sample is too fragmentary, the prevailing zonal arrangement of steatosis must also be noted.The Zone 3 (centrizonal), zone 1is (periportal),then panacinar periacinar, and the azonal are the four different patterns of zonal distribution. In adult NAFLD, zone 3 and panacinar seasonal changes are common. Adult patients with significant zone 1 distribution are uncommon (1%), however paediatric patients with predominant zone 1 distribution are more common (12%). Azonal distribution is more frequent in people with extensive

fibrosis, hepatocellular ballooning, and Mallory-Denk bodies.[21]

As in occurrence of steatosis with lobular / systemic inflammation, the diagnosing of "steatosis with inflammation" can also be proceeded. Steatosis with inflammation is not the same as steatohepatitis by description.[22] Even though it is linked to steatohepatitis and severe fibrosis, other causes of chronic hepatitis should be considered, including viral hepatitis C, that is characterised by minor steatosis and portal lymphocytic inflammation with lymphoid follicles. Prevailing portal inflammation surpassed lobular inflammation can be ubiquitous in chidrens.[23]

Steatosis with or without inflammation can also been referred to as simple steatosis. Simple steatosis is thought to be a benign, non-progressive illness followed by the deep survival rates comparable to the normal population, whereas steatohepatitis is linked to an elevation in the risk death related to liver. Conversely, Wong *et al*. found that in follow-up biopsies over a 3-year period, 58 percent,28 percent people with simple fatty change in liver had significant clinical outcomes and fibrosis advancement, respectively.[24]Furthermore, hepatic steatosis may cause oxidative fat damage, endoplasmic reticulum disruption, and cytoskeleton instabilities, resulting in hepatocellular ballooning, a hallmark of steatohepatitis. Although more research is needed to confirm that simple steatosis is a prospectively progressive lesion, it is important to remember that simple steatosis may not be dormant in all time.[25]

Over view on Steatohepatitis

Ballooning of hepatocytes, inflammation, and a high level of steatosis characterise the pathology of Hepatic impairment. "Bad" (LDL) cholesterol or excessive triglycerides, or low HDL cholesterol. and the type 2 diabetes.[26]Hepatocellular ballooning, which is characterised by the cellular enlargement, Hepatocytic cytosol rarefaction and grouped strand of intermediate filaments, distinguishes steatohepatitis from steatosis with inflammation. Fat droplet accumulation, endoplasmic reticulum dilatation, and cytoskeletal damage all leads to the development of inflated hepatocytes.[27]

Swollen hepatocytes are usually found in the centrizonal region in the early stages of steatohepatitis. The centrizonal distribution of Ballooning of hepatocytes disappeared in late-stage or very aggressive steatohepatitis.[28] Mallory-Denk bodies, also known as Mallory bodies or Mallory hyalines, are common in hepatocytes that have inflated. Regardless of cell size, ballooned hepatocytes will have a transparent, non-steatotic cytoplasm with a lack of acute angles. When inflated hepatocytes are stained with an

immunohistochemical stain for CK8/18, they show typical reduction of CK8/18 cytoplasmic expression, with remaining antibody limited to their Mallory-Denk structures if present. However, traditional H&E sections are still used to diagnose hepatocellular ballooning, and immunohistochemistry may be used as a supplement in equivocal instances.[29]

We now have a better grasp of the pathophysiologic mechanisms of NAFLD, which has led us to research medicines that rectify metabolic imbalances or have insulin responsiveness Peroxisome proliferator-activated receptors (PPARs) are a nuclear receptor transcriptionally family ligand (PPARs).[30] Each of the three PPAR isoforms, alpha (α), beta/delta (β/δ), and gamma (γ), has a distinct expression pattern in different organs. There is widespread expression of PPARα in the body, however it is concentrated with in liver.[31] Ppar-β/δ is mainly expressed in muscle, with smaller amounts in adipose tissue and the epidermis.[32] Whereas Ppar γ is widely expressed in fat cells.[33]

Fibrosis

Fibrosis a cytologic characteristic that indicates the severity of the disease and how far it has progressed. Despite the fact that it is not an demonstrative test for steatohepatitis it is seen in over 80% of individuals with NASH, regardless of age.[34]The hallmark characteristics of fibrosis in fatty liver disease includes centrizonal fibrosis and pericellular or perisinusoidal fibrosis, which indicate the fibrous tissue depositing in the Disse space coupled with the activity stellate cells. It is common in the initial stages of fibrosis in adults with NAFLD/NASH, and they're comparable to ALD. In comparison to ALD, the fibres in NAFLD/NASH are more thin and less noticeable. As the illness develops, periportal fibrosis and bridging fibrosis will occur. Cirrhosis will eventually develop as a result of chronic hepatic damage, fibrosis, parenchymal extinction, and hepatocellular regeneration. An satisfactory grade connective stain for tissue is required for the accurate fibrotic evaluation.[35] The masson trichrome, Gordon-Sweets reticulin, and also the red stains of Sirius are all stains found in connective tissue found in pathology of the hepatic membrane. A successful trichrome stain necessitates a sufficient phase of differentiation, which is generally accomplished with phosphomolybdic acid. Over- or understaining can result from insufficient or excessive differentiation, which can progress an over or to This amount of scarring is underestimated. Although it offers incredibly with detailed and contrast staining and it can be more sensitive in identifying moderate pericardial fibrosis, Sirius red staining is suggested for odontometric quantification

of fibrosis.[36] The collagen proportional area [CPA] defined by the computer-assisted image analysis was found to be more accurate and reliable than cytological stage in assessing fibrosis, and Sirius red staining for CPA determination was found to be more accurate and reliable than trichrome staining in contextualising fibrosis. One flaw in fibrosis pathology evaluation should be noted.[37]

Borderline steatohepatitis

Definite steatohepatitis is used to describe patients that have all of the diagnostic characteristics of steatohepatitis, usually with a centrifugal distribution. Borderline steatohepatitis refers to the stage of steatosis, with or without inflammation, that occurs between steatosis and confirmed steatohepatitis.[38] Two types of borderline steatohepatitis is mentioned in the NAFLD-CRN. The first is that the zone 3 borderline steatohepatitis, which may be utilized in cases that doesn't have any full-fledged, unmistakable histological characteristics of this definitive steatohepatitis such as which has characteristic centrizonal/ perisinusoidal fibrosis in the truancy of Ballooning of hepatocytes, and some with equivocal hepatocellular ballooning Zone one of borderline steatohepatitis, which is characterised by portal-based damage, is the second kind.[39] In most cases, hepatocellular ballooning is either nonexistent or minor. This unique type of borderline steatohepatitis is a distinct histological pattern that is more commonly seen in juvenile NASH patients [75 percent]. In the literature, it's also known as the type 2 NASH (as opposed like "type 1" NASH in adults) or pediatric NASH.[40]

Cryptogenic cirrhosis

When a thorough examination, cryptogenic cirrhosis can be diagnosed after the viral hepatitis, metabolic, immunological, and Cholestatic hepatic disorders have been ruled out. It is a prevalent reason for transplantation of the liver, accounting for about 7-14 percent of the patients who require the procedure.[41]One of the most common causes of cryptogenic cirrhosis is nonalcoholic fatty liver disease (NAFLD). Patients with cryptogenic cirrhosis have a comparable incidence of diabetes mellitus and obesity to those with NAFLD, but considerably outnumber those with cirrhosis caused by persistent viral hepatitis or autoimmune hepatitis.

Further NAFLD pathologic abnormalities

Some pathological alterations that are utilised to categorise the illness pattern are briefly discussed below. NAFLD and ALD, consuming the mineral oil in food and medicine can all cause lipogranuloma, which is the loose aggregates of

lymphocytes and the histiocytes around a globule.[42] Glycogenated nuclei are the result of glycogen buildup in the nucleus, and they are more prevalent in NAFLD than in ALD. They are not pathognomic for NAFLD, despite the fact that they are most likely the consequence of poor glucose tolerancing capacity or the insulin resistance. This can happens in children and young adults in a natural way (11 percent and 4 percent in the 20s and early age of 30)

Intranuclear eosinophilic glob or needle-shaped deposits are bigger while comparing with the nucleus of hepatocytes can be called as giant mitochondria or mega mitochondria. They are most commonly detected in alcoholic and non-alcoholic fatty liver disorders, but it can also be present in the various physiologic and pathologic situations like ageing, acute fatty liver of pregnancy, glycogen storage disease, and urea cycle abnormalities.[43]Cirrhosis of the liver is observed in women in their late teens and early twenties. For example, autoimmune hepatitis is more frequent in women than in males and can start at a young age, causing stomach discomfort, jaundice, tiredness, and weight loss.

Obesity is linked to the increased frequency and incidence of non-alcoholic fatty liver disease (NAFLD). Adiposity is also linked to more than just steatosis (SS), along with advanced disease, like non-alcoholic steatohepatitis (NASH),NASH related cirrhosis, hepatocellular carcinoma.[44]As a result, apart from increasing all-cause mortality, obesity increases the liver-specific mortality in NAFLD patients .Obesity along with other metabolic conditions, which includes diabetes, Inside the metabolic syndrome, dyslipidemia and hypertension are frequently coupled and can also be the Non-alcoholic fatty liver disease (NAFLD), a ‘fellow traveller' with the insulin resistance, has risk factors.[45] The significant prevalence of NAFLD (approximately adult population of about 25%, rising to 76 percent in type 2 diabetes mellutis) and its associated along with health concerns demonstrate that primary and secondary prevention must be prioritised.[46]

Patients with NAFLD-related cirrhosis have a higher chance of developing HCC, with an annual incidence of 2% to 3%. Steatohepatitic HCC is a newly described histological variant of HCC that has Steatosis in some more than 5% of tumour cells, Ballooning of hepatocytes, Mallory-Denk bodies, intratumoral inflammatory infiltration, and perisinusoidal fibrosis are all symptoms of steatohepatitis, which is associated to underlying NAFLD and physiological hazards.[47]

Techniques supporting pathological grade, stage, and score

Grading is a way of determining how active an illness is, whereas staging is a way of determining how long it has been active. Besides decades, grading and staging processes have been used in persistent liver cirrhosis provide the semiquantitative assessments of the severity and progression of disease, as well as to enhance the efficacy of treatment guidelines, standardisation of pathology reportage, and the facilitation of scientific studies. It was based on screening mammography from 51 NAFLD patients. A combination of histological characteristics, involving steatosis, lobular, portal inflammation, and hepatocellular ballooning, were used to determine the symptom severity grade (0-3).[48]Adult NAFLD fibrosis patterns ranging from cirrhosis, bridging, and centrizonal/perisinusoidal, and the fibrosis stage (0-4) was determined. Primary disease (First stage) was then separated into 1a which is (mild perisinusoidal fibrosis visible only by the stain in connective tissue), 1b (moderate perisinusoidal fibrosis visualised only by H&E section), and 1c (portal/periportal fibrosis only by H&E section) in the fibrosis staging.[49] Although more than value of 5 of NAS has been utilised as an inclusion criteria in clinical studies of patients with NASH treatment, it can be remembered that NAS is not considerable as the criteria for the diagnosis of steatohepatitis (i.e., steatohepatitis diagnosis can be carried out only if when the NAS is more than 5). An algorithm published by the Bedossa *et al* shows a score system in 2012, based on a cohort of about 679 obese individuals who had Weight loss popularly (bariatric surgery).[50] By the semi -quantitatifying assessment of the steatosis, ballooning of hepatocytes, and the lobular inflammation, FLIP [fatty liver inhibition of progression] algorithm which suggests the separation lesions into the normal liver, or damaged liver.[51] The [steatosis, activity, fibrosis] score combines fatty change, activities like [Ballooning of the hepatocells and inflammation in the lobules], and fibrosis scores. Steatosis is not included in the activity scores as compared to NASH-CRN system since the predictive relevance of steatosis in disease development is still debated. Further research on the therapeutic trials of the FLIP/SAF system is needed.[52]

DRAWBACK'S OF LIVER AUTOPSY

Despite the fact that a liver biopsy is the best model for detecting liver cancer, NAFLD/NASH, it does have certain constrations.To begin with, it is an invasive surgery with a high complications and mortality rate of 0.58 percent and 0.01% sequentionally.[53] Minor problems include temporary discomfort at the biopsy site, pain that requires painkiller, vasovagal attack, and transitory moderate hypotension. However, when the number of

passes is increased, complications become more common.In the hands of a skilled operator and under imaging monitoring Second, just a tiny percentage (0.001-0.002 percent) of the total liver is sampled in liver biopsy, resulting in sampling error.[54] Due to the fact that just one-fiftieth of the whole liver tissue is taken during a liver biopsy, the We recommend that you gather enough tissue to avoid sampling mistakes, which means that you should use a thick needle and collect two or more samples of suitable length.

In order to make an appropriate diagnosis of NASH, specimens must be at least 15-16 mm long.[55] According to Ratziu *et al*, NAFLD patients were each given two percutaneous liver biopsy samples, with the consistency of fatty change being reasonably high (78 percent), but the fibrosis stage being different between the two samples in 41 percent of the patients.[56]One study found that in 35 percent of the patients with bridging fibrosis identified in one sample, there was only moderate or no fibrosis in the other. [57] Inflammatory findings were also more inconsistent between left and right lobe biopsies. It is recommended that, when the left lobe is biopsied before therapy, the left lobe should again be biopsied after treatment to assess the therapeutic impact, according to AASLD's recently established assessment criteria for pathological diagnosis.[58]

Receptor differential diagnoses

Nuclear receptor superfamily's PPARs comprise the PPAR- α , β / δ , and γ, that can regulate cellular development and Development, metabolic, and inflammatory are all factors to consider. The protein phosphatase A receptor (PPAR) is (NR1C1) is strongly present in the liver, kidneys, and muscles, whereas PPAR- (NR1C3) is mostly found in the adipose tissues and PPAR- β / δ seems to be then revealed everywhere.59 The receptors were triggered by ligand in a traditional sense, and the best-studied Fatty acids (FA) and their derivatives are natural ligands of fatty acids. When PPARs get active, they create a heterodimer with the retinoid X receptor, This modulates target gene transcription of by binding to PPAR responsive regions.[60] PPARs regulates a wide stages of the physiological activities in the liver, which includes the cholesterol and bile acid homeostasis, metabolism glucolipids, inflammatory responses, regenerative mechanisms, differentiation of cell, cell cycle.

Functions of PPAR- α

The effects of the PPAR- α system in the activation of improved NAFLD and the spectrum have been investigated in many animal models that partially mimic the human illness. Various steatogenic

pathways have been employed in a couple of experimental diet-induced NAFLD animal models. Through activating genes associated in de novo lipogenesis [— for example, PPAR- alpha and also the sterol regulating component protein-1], the high-fat diet (HFD) can produce hyperlipidemia which is countered by PPAR- alpha overexpression, that is capable for catabolization of the excess FA load, but not enough to cause fatty liver.[61] The down rating of genes for the process of esterification of Fatty Acid and secretion of very-low-density lipoprotein that is caused by a methionine and choline deficient diet produces fatty liver without altering the expression of PPARs.[62] In terms of NASH, the HFD model effectively induces the MCD diet easily drives the progression from fibrosis to Non-alcoholic steatohepatitis, histologically identical while compared with diseases in human beings only without the les pairs phenotype, meanwhile NASH diet is not.[63] PPAR-deficient animals had histologically more severe NASH in the MCD diet NASH mouse model, and therapy beside a strong agonist (Wy-14,643) can cure the fibrosis and NASH in the wild-type mice. As PPAR—null mice are fed an HFD, they develop cell damage, histologic steatosis, liver inflammatory, and a greater NAFLD Activity Score (NAS) than maturity level wild-type mice fed a regular or PPAR-alpha null mice were fedded with a regular feed.[64]

PPAR-agonism suppresses the effects of hepatic inflammation response and a transfer from fatty change to NASH and fibrosis by a straight anti-inflammatory action, according to a recent research and on FA metabolism of a Peroxisome proliferator - activated receptor model lacks the DNA-binding-dependent activity.65 The liver histological inflammation grade, on the other hand, do not change, and adiponectinemia and inflammatory (infiltration of inflammatory cells increases and MCP1 expression) remained stable whereas TNF-expression in adipose tissue reduced. These data imply that Inflammatory chemokines cause adipose tissue inflammation that does not inhibited is responsible for remaining hepatic inflammatory alteration, potentially reduction of the therapeutic efficacy of PPAR- alpha agonists in NASH.66 As Well, the beneficial role of PPAR-expression or activating by the fibrates on hepatic deposition of fats and inflammatory was already observed in the apolipoprotein-E2 knock-in animal models, which mimics human type of III hyperlipoproteinemia.67

In human beings, a latest paired liver biopsy research of about Eighty five patients found that the liver PPAR-alpha gene expression was contraindicately linked with IR, visceral obesity, severityof

fatty change in hepatic organ, presence of NASH, ballooning of hepatocytes, NAS, and fibrosis, but favourably linked with the adiponectin.68Histological improvement was linked to increase in the expression of PPAR-alpha and its targeting genes after a year. PPAR-beta/delta and PPAR-alpha expression in the liver were not linked to any histological features or gluco-lipidic metabolism. Fibrate agonists,like PPAR agonists,were beneficial in reduction of fatty change in rats, Although there is no completion is found in peoples.69

Through the PPARs system, diet can influence NAFLD's growth and continuation. PPARs are activated by the dietary monounsaturated fatty acids (MUFA), Polyunsaturated fatty acids (PUFA), and proteins, that can increase oxidation of lipids and decrease inflammation and the IR, resulting in a reduction in hepatic steatosis. [70] Furthermore, these nutrients can decrease liver fat by inhibiting the expression of the transcription factor like SREBP-1, which controls the expression of genes involved in hepatic lipogenesis from scratch. Obese people, for example, are more likely to develop steatosis due to the elevated SREBP-1c/PPAR- ratio linked to n-3 long chain PUFA reduction and IR, that can favour lipogenesis among oxidation of Fatty acids.71Supplementation of n-3 long chain PUFA suppresses High Fat Diet-induced increases the hepatic SREBP-1c/PPAR- alpha ratios in mice, encouraging enhanced FA oxidation and steatosis attenuation, and has an increased impact with ursodeoxycholic acid (UDCA) in relieving histological characteristics in High Fat Diet-induced NASH.As a result, there is contradictory data linking PPAR-genetic polymorphisms to human NAFLD susceptibility.72

The Significance of PPAR- γ in the Metabolic process

In adipose tissue, PPAR- delta is significantly observed., which promotes adipocyte development and TG accumulation by increasing gene activation.[73] Furthermore, PPAR- is a significant controller of Its insulin-sensitizing action helps to maintain glucose metabolism., as it protects non-adipose tissues from excess depositing of fats and regulates its generation of adipocytokines.[74]

PPAR- γ 's Impact on NAFLD

Exclusive of steatosis produced by the Methionine Choline Deficient diet, which was discussed before, PPAR-gamma is typically elevated in fatty liver and is linked with obesity in both mice models and humans.[75] According to this claim, mice studies which is fed with the High Fat Diet show that hepatocyte-specific PPAR deletion and it shields against hepatic steatosis but that PPAR knockdown is done using an RNA interfering-

adenoviral vector that injection cures fatty liver.[76] Given the fact that all these studies say PPAR- agonists have a detrimental impact on NAFLD, a net impact of thiazolidinedione PPAR- agonists in the mouse liver results in an increased hepatic fatty change along with the safety from Non-alcoholic steato hepatitis and hepatic fibrosis mostly through increase in insulin levels of adipose tissue and in the skeletal muscles, which overcomes specific steatogenic impacts on hepatocytes.[77]In the liver and adipose tissue, PPAR- agonism boosts adiponectin synthesis and receptor expression, improvement in the insulin levels and in increasing hepatic Fatty acid oxidation. Increased expression of PPAR inhibits activation of hepatic stellate cells, which lowers fibrosis in animals and in vitro studies.[78]

The C161T, Pro12Ala PPAR-gamma single nucleotide polymorphism (SNP) has been linked to NAFLD's growth and recurrence in humans, but a recent meta-analysis revealed that this link is only suitable for East Asians but not for Europeans.79The most commonly studied PPAR- γ agonists were thiazolidinediones (TZDs). TZDs are a class of insulin-sensitizing medicines that are now utilised in clinical practise that includes rosiglitazone and pioglitazone.80 Enhanced synthesis of numerous adipokines, notably adiponectin, is a result of PPAR- γ stimulation by TZDs, that improves hepatic fatty acid oxidation.[80]

TZDs are expected and reduce inflammation and the production of cytokines in patients with some metabolic syndrome, in addition to their metabolic changes.[81]TZDs have been shown to improve metabolic profiles and insulin sensitivity in a variety of animal investigations.[81]It appears that TZDs also ameliorate certain characteristics of NASH, like fattychange and inflammation, Although this isn't true in all cases. TZDs, which are therapeutically utilized, as well as other PPAR- γ agonists are discussed in depth below.82

Rosiglitazone is the most powerful PPAR-γ ligand of the TZDs, and it has the It has been shown that rosiglitazone has little or no effect on hepatic steatosis. Rosaglitazone's high activation of PPAR in the steatotic mice liver may induce the presence of fat storage genes.[83] When rosiglitazone was administered to other animal models, however, it decreased the amount of hepatic steatosis. It is important to note that rosiglitazone has been shown to reduce inflammation and prevent or reverse fibrosis as well as activation of liver stellate cells. For example, CCl4 was used to treat mice with steatohepatitis caused by an MCD diet, as well as mice with LDLR/ that were fed a high fat.[84] A worsening of steatosis has not been observed in clinical

research using PPAR- γ agonists, as stated below. Once again, these disparities emphasise the differences PPARs in rodents as well as in humans, also the difficulty of transferring preclinical data.[85]

For the treatment of NAFLD and NASH, rosiglitazone has been tested in people Patients with biopsy-confirmed NASH were included in a study that did not include a placebo control group to evaluated the influence of 48 weeks of rosiglitazone.[86] A little over at the start of the trial, majority of the individuals had hyperglycemia or diabetes.. There was a significant decline in ALT levels and statistical improvements in HOMA-IR and QUICKI after treatment In addition, 45 percent of patients no longer satisfied the requirements for NASH diagnosis, according to histologic evaluations of the liver.[87] A significant statistical improvement has been seen in the zone 3 perisinusoidal fibrosis score, but there was no change in the overall fibros Unfortunately, the drug rosiglitazone was linked with considerable increase in weight of the vast majority of the patients, despite improved histology results and enhanced insulin sensitivity. Another disappointment was that ALT levels reverted to pre-treatment levels within six months of stopping rosiglitazone.[88]

The FLIRT trial evaluated the efficacy of rosiglitazone in a randomised, placebo-controlled experiment. Rosiglitazone-treated patients were more likely than placebo-treated patients to show improvement in hepatic steatosis and normalisation of blood ALT.[89]Hepatocyte ballooning and swelling did not improve much. In the FLIRT2 extension experiment, 44 patients (22 on placebo and 18 on rosiglitazone) were given rosiglitazone for an additional 2 years after starting the trial.[90] There has been no substantial improvement in NASH, inflammation, fibrosis, or hepatocyte ballooning for patients referred to the therapy group in the FLIRT experiment after an additional two years.[91]This means that ineffectiveness can't be blamed on insufficient treatment time, that even patients who got three years of treatment had inflammation or scarring are unaffected.. Like the improvements in the steatosis, then greatest increase in insulin levels tends to happen after one year of rosiglitazone medication.[92] During a randomised, controlled clinical trial, Torres and coworkers investigated the effects of rosiglitazone. Rosiglitazone alone was tested against rosiglitazone plus metformin and rosiglitazone plus losartan in order to decide which was more effective.[93] In all three groups, ALT and histological characteristics have improved since the beginning of Unfortunately, none of the groups differs markedly from one another,

signaling that the inclusion of supplemental medicines (at least in the context of metformin and losartan).[94]

The Function of PPAR- β/δ in NAFLD

PPAR- β/δ regulates metabolism of glucose and lipoproteins in the liver while also acting as an anti-inflammatory. Experimental investigations in animal models are the major source of information on PPAR- β/δ physiopathology.[95]

In HFD-fed animals, Hepatic PPAR- β/δ activity increases consumption of the glucose while inhibiting gluconeogenesis, according to a research PPAR- β/δ knockout mice had hypertriglyceridemia and glucose intolerance. PPAR- β/δ agonists, on the other hand, decrease plasma TG levels.[96]

The impact of PPAR- β/δ in lipid metabolism in the liver is still up for debate. Upregulation of the PPAR gene in the liver by adenoviral infection can be linked to the better (in obese db/db animals) or the worsened hepatic fatty change (in HFD-fed mice liver).[97]PPAR- β/δ activation enhances the synthesis of beneficial MUFA and, contrarily, lowered lipotoxic saturated FA concentrations in the blood, resulting in less liver damage in High Fat Diet-fed mice despite increases fatty change.[98]Furthermore, when PPAR- β/δ deficient animals were given a hepatotoxic substance, they developed greater necrosis in liver, inflammation, then increased expression of profibrotic genes than control mice, suggests that PPAR- β/δ protects the liver from fibrosis and inflammation.[99]

Several studies using particular PPAR- β/δ agonists (such as GW501516, GW0742, and L-165041) in animal models shown that NR activation improved fatty liver by modulating Fatty acid metabolism (increased -oxidation and decreased FA production) and reducing IR and inflammatory activity. Treatment with PPAR- β/δ agonists improved NASH histological characteristics as well.[100] PPAR- Beta/delta agonists (GW501516 or MBX-8025) improved metabolic characteristics (IR, plasmatic TGs, nonesterified FA [NEFA], apolipoprotein B-100, LDL-cholesterol), liver enzymes, and liver fat content in two clinical studies on overweight people.[101] It should be emphasised, however, that the only study that looked at the effect of the PPAR- β/δ agonist GW501516 on steatosis was a tiny pilot study.[102]

In mouse models of NAFLD/NASH and liver fibrosis, the recently found dual PPAR- β/δ agonist GFT505 has exhibited protective benefits Both PPAR-dependent and PPAR-independent pathways are involved in liver steatosis, inflammation, and fibrosis.[103]In obese adults, GFT505 lowered hepatic and peripheral IR. GFT505

will be discussed more in the section below under "Dual" PPAR- β/δ Agonists.[104]

CONCLUSION

The significance of Nuclear receptor's in NAFLD pathogenesis, natural history, and treatment is still under investigation, and more research is needed. Although PPAR agonists appear to reduce steatosis and necroinflammation in NAFLD. There is no licence for the use of thiazolidinediones in the management of NASH, there is little data in diabetics, and lengthy and efficacy in NASH patients remain unknown. Elafibranor, a dual PPAR-/agonist, has shown encouraging effects and has a favourable safety profile, but its efficacy needs to be verified. By alleviating all of the histological characteristics of NASH, including fibrosis, Cirrhosis can be prevented by FXR agonist OCA. To validate this potential and to address concerns regarding tolerance and side effects, more study is needed. There is also a pressing need for drugs that interact with several NRs, whether they are discussed here, such as the LXR or not, such as PXR, the constitutive androstane receptor (CAR), the LRH-1, the oestrogen receptor beta, the thyroid hormone receptor beta, and the VDR, whose significance has indeed been revealed in NAFLD animal studies.

Acknowledgments

We thank Prof. V. Chitra, M.Pharm., Ph.D.,Dean, SRMIST College of Pharmacy and staff for providing the necessary guidance for this review to be successful.

Declaration of conflict of interest(s)

"There are no potential conflicts of interest to declare."

Funding source

The author(s) received no financial support for the review, authorship, and/or publication of this article.

REFERENCES

[1] Pu S, Wu X, Yang X, Zhang Y, Dai Y, Zhang Y, Wu X, Liu Y, Cui X, Jin H, Cao J. The therapeutic role of xenobiotic nuclear receptors against metabolic syndrome. Current drug metabolism. 2019 Jan 1;20(1):15-22.

[2] Tanaka N, Aoyama T, Kimura S, Gonzalez FJ. Targeting nuclear receptors for the treatment of fatty liver disease. Pharmacology & therapeutics. 2017 Nov 1;179:142-57.

[3] Cave MC, Clair HB, Hardesty JE, Falkner KC, Feng W, Clark BJ, Sidey J, Shi H, Aqel BA, McClain CJ, Prough RA. Nuclear receptors and nonalcoholic fatty liver disease. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms. 2016 Sep 1;1859(9):1083-99.

[4] Molla NW. *Does Liver Regeneration After Liver Resection for Colorectal Liver Metastases Affect Recurrence Rate? A Study of Liver Volumetrics* (Doctoral dissertation, McGill University (Canada)).

[5] Yu J, Marsh S, Hu J, Feng W, Wu C. The pathogenesis of nonalcoholic fatty liver disease: interplay between diet, gut microbiota, and genetic background. Gastroenterology research and practice. 2016 May 9;2016.

[6] Shen M, Lee A, Lefkowitch JH, Worman HJ. Vibration-controlled Transient Elastography for Assessment of Liver Fibrosis at a USA Academic Medical Center. Journal of Clinical and Translational Hepatology. 2021 Aug 13(000):0-.

[7] Neuberger J, Patel J, Caldwell H, Davies S, Hebditch V, Hollywood C, Hubscher S, Karkhanis S, Lester W, Roslund N, West R. Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology. Gut. 2020 Aug 1;69(8):1382-403.

[8] Liebe R, Esposito I, Bock HH, Vom Dahl S, Stindt J, Baumann U, Luedde T, Keitel V. Diagnosis and management of secondary causes of steatohepatitis. Journal of Hepatology. 2021 Feb 10.

[9] Plaza-Díaz J, Solis-Urra P, Aragón-Vela J, Rodríguez-Rodríguez F, Olivares-Arancibia J, Álvarez-Mercado AI. Insights into the impact of microbiota in the treatment of NAFLD/NASH and its potential as a biomarker for prognosis and diagnosis. Biomedicines. 2021 Feb;9(2):145.

[10] Itsiopoulos C, Tierney A. Early and middle adult (26–60 years). InFood & Nutrition Throughout Life 2020 Jul 16 (pp. 212-230). Routledge.

[11] Alqahtani SA, Broering DC, Alghamdi SA, Bzeizi KI, Alhusseini N, Alabbad SI, Albenmousa A, Alfaris N, Abaalkhail F, Al-Hamoudi WK. Changing trends in liver transplantation indications in Saudi Arabia: from hepatitis C virus infection to nonalcoholic fatty liver disease. BMC gastroenterology. 2021 Dec;21(1):1-0.

[12] Soto-Angona Ó, Anmella G, Valdés-Florido MJ, De Uribe-Viloria N, Carvalho AF, Penninx BW, Berk M. Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches. BMC medicine. 2020 Dec;18(1):1-4.

[13] Papachristodoulou A, Kavvadas D, Karamitsos A, Papamitsou T, Chatzidimitriou M, Sioga A. Diagnosis and Staging of Pediatric Non-Alcoholic Fatty Liver Disease: Is Classical Ultrasound the Answer?. Pediatric Reports. 2021 Jun;13(2):312-21.

[14] Geier A, Tiniakos D, Denk H, Trauner M. From the origin of

NASH to the future of metabolic fatty liver disease. Gut. 2021 Feb 25.

[15] Marti-Aguado D, Rodríguez-Ortega A, Mestre-Alagarda C, Bauza M, Valero-Pérez E, Alfaro-Cervello C, Benlloch S, Pérez-Rojas J, Ferrández A, Alemany-Monraval P, Escudero-García D. Digital pathology: accurate technique for quantitative assessment of histological features in metabolic-associated fatty liver disease. Alimentary Pharmacology & Therapeutics. 2021 Jan;53(1):160-71.

[16] Costa AM. *The impact of different lipogenic diets on direct and indirect pathway contributions to hepatic glycogen synthesis* (Doctoral dissertation, Universidade de Coimbra).

[17] Elßner C. *The role of non-canonical NF-kB for liver homeostasis, chronic liver injury and hepatocarcinogenesis* (Doctoral dissertation).

[18] Sergi CM. Parenchymal GI Glands: Liver. InPathology of Childhood and Adolescence 2020 (pp. 425-549). Springer, Berlin, Heidelberg.

[19] Chen YY, Yeh MM. Non-alcoholic fatty liver disease: A review with clinical and pathological correlation. Journal of the Formosan Medical Association. 2021 Jan 1;120(1):68-77.

[20] Yuan XZ, Yang RM, Wang XP. Management perspective of Wilson's disease: early diagnosis and individualized therapy. Current neuropharmacology. 2021 Apr 1;19(4):465-85.

[21] Lefkowitch JH. Scheuer's liver biopsy interpretation E-Book. Elsevier Health Sciences; 2020 Mar 28.

[22] Radhakrishnan S, Ke JY, Pellizzon MA. Targeted nutrient modifications in purified diets differentially affect nonalcoholic fatty liver disease and metabolic disease development in rodent models. Current Developments in Nutrition. 2020 Jun;4(6):nzaa078.

[23] Lefere S, Onghena L, Vanlander A, Van Nieuwenhove Y, Devisscher L, Geerts A. Bariatric surgery and the liver—Mechanisms, benefits, and risks. Obesity Reviews. 2021 May 18:e13294.

[24] Jashari A. Alterations of the glyoxylate metabolism in hepatic steatosis–a risk factor for hyperoxaluria.

[25] Rungratanawanich W, Qu Y, Wang X, Essa MM, Song BJ. Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue

injury. Experimental & Molecular Medicine. 2021 Feb;53(2):168-88.

[26] Scapaticci S, D'Adamo E, Mohn A, Chiarelli F, Giannini C. Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes. Frontiers in Endocrinology. 2021;12.

[27] Sergi CM. Parenchymal GI Glands: Liver. InPathology of Childhood and Adolescence 2020 (pp. 425-549). Springer, Berlin, Heidelberg.

[28] Doherty a. Chapter four acute and chronic viral hepatitis amanda doherty, MD LI Juan Wang, MD, PHD Xiuli Liu, MD, PHD. Practical Interpretation of Liver Biopsy, Volume 1. 2020 Nov 24;1:108.

[29] Wang L, Yu S, Chan AW. Pathology of non-alcoholic fatty liver disease. Int. J. Dig. Dis. 2016 Jan;2(353):354.

[30] Grover A, Sharma K, Gautam S, Gautam S, Gulati M, Singh SK. Diabetes and Its Complications: Therapies Available, Anticipated and Aspired. Current Diabetes Reviews. 2021 May 1;17(4):397-420.

[31] Rudko OI, Tretiakov AV, Naumova EA, Klimov EA. Role of PPARs in Progression of Anxiety: Literature Analysis and Signaling Pathways Reconstruction. PPAR research. 2020 Nov 30;2020.

[32] Iannotti FA, Vitale RM. The endocannabinoid system and PPARs: focus on their signalling crosstalk, action and transcriptional regulation. Cells. 2021 Mar;10(3):586.

[33] Dennis A, Mouchti S, Kelly M, Fallowfield JA, Hirschfield G, Pavlides M, Banerjee R. A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis. Scientific reports. 2020 Sep 17;10(1):1-1.

[34] Nicoară-Farcău O, Rusu I, Stefănescu H, Tanțău M, Badea RI, Procopeț B. Diagnostic challenges in non-cirrhotic portal hypertension-porto sinusoidal vascular disease. World Journal of Gastroenterology. 2020 Jun 14;26(22):3000.

[35] Waghorn PA, Ferreira DS, Erstad DJ, Rotile NJ, Masia R, Jones CM, Tu C, Sojoodi M, Yin-ching IC, Schlerman F, Wellen J. Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis. Scientific Reports. 2021 Mar 17;11(1):1-2.

[36] Brown DL. Immunopathology of the Hepatobiliary System. InImmunopathology in Toxicology

and Drug Development 2017 (pp. 329-417). Humana Press, Cham.

[37] Yilmaz Y, Kurt R, Eren F, Imeryuz N. Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: association with ballooning degeneration. Scandinavian journal of clinical and laboratory investigation. 2011 Dec 1;71(8):631-6.

[38] Dufour JF, Scherer R, Balp MM, McKenna SJ, Janssens N, Lopez P, Pedrosa M. The Global Epidemiology of Nonalcoholic Steatohepatitis (NASH) and Associated Risk Factors–A Targeted Literature Review. Endocrine and Metabolic Science. 2021 Feb 24:100089.

[39] Vandel J, Dubois-Chevalier J, Gheeraert C, Derudas B, Raverdy V, Thuillier D, Gaal L, Francque S, Pattou F, Staels B, Eeckhoute J. Hepatic molecular signatures highlight the sexual dimorphism of nonalcoholic steatohepatitis (NASH). Hepatology. 2021 Mar;73(3):920-36.

[40] Hadzic N, Baumann U, MCLIN V. Pediatric Liver Transplantation E-Book: A Clinical Guide. Elsevier Health Sciences; 2020 Nov 13.

[41] Pirow R, Blume A, Hellwig N, Herzler M, Huhse B, Hutzler C, Pfaff K, Thierse HJ, Tralau T, Vieth B, Luch A. Mineral oil in food, cosmetic products, and in products regulated by other legislations. Critical reviews in toxicology. 2019 Oct 21;49(9):742-89.

[42] Lian CY, Zhai ZZ, Li ZF, Wang L. High fat diet-triggered non-alcoholic fatty liver disease: a review of proposed mechanisms. Chemico-Biological Interactions. 2020 Aug 15:109199.

[43] Kumar R, Priyadarshi RN, Anand U. Non-alcoholic fatty liver disease: growing burden, adverse outcomes and associations. Journal of clinical and translational hepatology. 2020 Mar 28;8(1):76.

[44] Tillman EJ, Rolph T. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Frontiers in Endocrinology. 2020;11.

[45] Spiritos Z, Abdelmalek MF. Metabolic syndrome following liver transplantation in nonalcoholic steatohepatitis. Translational Gastroenterology and Hepatology. 2021;6.

[46] Kim H, Jang M, Park YN. Histopathological variants of hepatocellular carcinomas: an update according to the 5th edition of the WHO classification of digestive system tumors.

[47] Lonardo A, Leoni S, Alswat KA, Fouad Y. History of nonalcoholic

fatty liver disease. International Journal of Molecular Sciences. 2020 Jan;21(16):5888.

[48] Carter-Kent C, Yerian LM, Brunt EM, Angulo P, Kohli R, Ling SC, Xanthakos SA, Whitington PF, Charatcharoenwitthaya P, Yap J, Lopez R. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology. 2009 Oct;50(4):1113-20.

[49] Tachezy M, Sognamiglio P, Reeh M, Karstens K, Bellon E, Kantowski M, Schön G, Zapf A, Chon SH, Izbicki J. Endoscopic Vacuum Therapy versus Stenting for postoperative esophago-enteric Anastomotic Leakage: Systematic Review and Meta-Analysis.

[50] Forlano R, Mullish BH, Giannakeas N, Maurice JB, Angkathunyakul N, Lloyd J, Tzallas AT, Tsipouras M, Yee M, Thursz MR, Goldin RD. High-Throughput, machine learning–based quantification of steatosis, inflammation, ballooning, and fibrosis in biopsies from patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology. 2020 Aug 1;18(9):2081-90.

[51] Liu F, Goh GB, Tiniakos D, Wee A, Leow WQ, Zhao JM, Rao HY, Wang XX, Wang Q, Wan WK, Lim KH. qFIBS: an automated technique for quantitative evaluation of fibrosis, inflammation, ballooning, and steatosis in patients with nonalcoholic steatohepatitis. Hepatology. 2020 Jun;71(6):1953-66.

[52] Kogachi S, Noureddin M. Noninvasive evaluation for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clinical Therapeutics. 2021 Feb 10.

[53] Achampong KB. *Changes in Selected Biochemical Parameters in Thermal Burns Patients at the Korle Bu Teaching Hospital* (Doctoral dissertation, University Of Ghana).

[54] Cariello M, Piccinin E, Moschetta A. Transcriptional regulation of metabolic pathways via lipid-sensing nuclear receptors. Cellular and Molecular Gastroenterology and Hepatology. 2021 Feb 2.

[55] Tjen HS. Cholescintigraphy.

[56] Smith BW, Adams LA. Non-alcoholic fatty liver disease. Critical reviews in clinical laboratory sciences. 2011 Jun 1;48(3):97-113.

[57] Vilar-Gomez E, Sookoian S, Pirola CJ, Liang T, Gawrieh S, Cummings O, Liu W, Chalasani NP. ADH1B∗ 2 Is Associated With Reduced Severity of Nonalcoholic Fatty Liver Disease in Adults, Independent of Alcohol Consumption. Gastroenterology. 2020 Sep 1;159(3):929-43.

[58] Higuchi R, Nakagomi T, Goto T, Hirotsu Y, Shikata D, Yokoyama Y, Otake S, Amemiya K, Oyama T, Mochizuki H, Omata M. Identification of clonality through genomic profile analysis in multiple lung cancers. Journal of clinical medicine. 2020 Feb;9(2):573.

[59] Rosenfeld JM, Kao HY, Evans RM. The nuclear receptor superfamily. Hormones, Genes, and Cancer. 2003 Mar 13:38.

[60] Gross B, Pawlak M, Lefebvre P, Staels B. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nature Reviews Endocrinology. 2017 Jan;13(1):36-49.

[61] Ingebrigtsen MV. *The effects of different diets on obesity and liver steatosis in mice* (Master's thesis).

[62] Rives C, Fougerat A, Ellero-Simatos S, Loiseau N, Guillou H, Gamet-Payrastre L, Wahli W. Oxidative stress in NAFLD: Role of nutrients and food contaminants. Biomolecules. 2020 Dec;10(12):1702.

[63] Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Current pharmaceutical design. 2013 Sep 1;19(29):5250-69.

[64] Boeckmans J, Natale A, Rombaut M, Buyl K, Rogiers V, De Kock J, Vanhaecke T, Rodrigues RM. Anti-NASH drug development hitches a lift on PPAR agonism. Cells. 2020 Jan;9(1):37.

[65] Fougerat A, Montagner A, Loiseau N, Guillou H, Wahli W. Peroxisome proliferator-activated receptors and their novel ligands as candidates for the treatment of non-alcoholic fatty liver disease. Cells. 2020 Jul;9(7):1638.

[66] Cariello M, Piccinin E, Moschetta A. Transcriptional regulation of metabolic pathways via lipid-sensing nuclear receptors. Cellular and Molecular Gastroenterology and Hepatology. 2021 Feb 2.

[67] Kucukoglu O, Sowa JP, Mazzolini GD, Syn WK, Canbay A. Hepatokines and adipokines in NASH-related hepatocellular carcinoma. Journal of hepatology. 2020 Nov 5.

[68] Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Lonardo A. The role of nuclear receptors in the pathophysiology, natural course, and drug treatment of NAFLD in humans. Advances in therapy. 2016 Mar 1;33(3):291-319.

[69] Valenzuela R, Videla LA. Impact of the co-administration of N-3 fatty acids and olive oil components in preclinical nonalcoholic fatty liver disease models: a mechanistic view. Nutrients. 2020 Feb;12(2):499.

[70] Shin MR, Shin SH, Roh SS. Diospyros kaki and Citrus unshiu

Mixture Improves Disorders of Lipid Metabolism in Nonalcoholic Fatty Liver Disease. Canadian Journal of Gastroenterology and Hepatology. 2020 Dec 24;2020.

[71] Grattagliano I, Di Ciaula A, Baj J, Molina-Molina E, Shanmugam H, Garruti G, Wang DQ, Portincasa P. Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD). InMitochondrial Regulation 2021 (pp. 201-246). Humana, New York, NY.

[72] You W, Xu Z, Sun Y, Valencak TG, Wang Y, Shan T. GADD45α drives brown adipose tissue formation through upregulating PPARγ in mice. Cell death & disease. 2020 Jul 27;11(7):1-5.

[73] Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Molecular and cellular endocrinology. 2010 Jan 15;314(1):1-6.

[74] Yang Z, Li P, Shang Q, Wang Y, He J, Ge S, Jia R, Fan X. CRISPR-mediated BMP9 ablation promotes liver steatosis via the down-regulation of PPARα expression. Science advances. 2020 Nov 1;6(48):eabc5022.

[75] Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Lonardo A. The role of nuclear receptors in the pathophysiology, natural course, and drug treatment of NAFLD in humans. Advances in therapy. 2016 Mar 1;33(3):291-319.

[76] Mantovani A, Zusi C, Dalbeni A, Grani G, Buzzetti E. Risk of kidney dysfunction in NAFLD. Current pharmaceutical design. 2020 Mar 1;26(10):1045-61.

[77] Wu L, Guo C, Wu J. Therapeutic potential of PPARγ natural agonists in liver diseases. Journal of cellular and molecular medicine. 2020 Mar;24(5):2736-48.

[78] Sarhangi N, Sharifi F, Hashemian L, Doabsari MH, Heshmatzad K, Rahbaran M, Jamaldini SH, Meybodi HR, Hasanzad M. PPARG (Pro12Ala) genetic variant and risk of T2DM: a systematic review and meta-analysis. Scientific reports. 2020 Jul 29;10(1):1-8.

[79] Hansmann G, Calvier L, Risbano MG, Chan SY. Activation of the metabolic master regulator PPARγ: a potential PIOneering therapy for pulmonary arterial hypertension. American journal of respiratory cell and molecular biology. 2020 Feb;62(2):143-56.

[80] Morigny P, Boucher J, Arner P, Langin D. Lipid and glucose metabolism in white adipocytes: pathways, dysfunction and therapeutics. Nature Reviews

Endocrinology. 2021 May;17(5):276-95.

[81] Hauffe R, Stein V, Chudoba C, Flore T, Rath M, Ritter K, Schell M, Wardelmann K, Deubel S, Kopp JF, Schwarz M. GPx3 dysregulation impacts adipose tissue insulin receptor expression and sensitivity. JCI insight. 2020 Jun 4;5(11).

[82] Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nature Reviews Endocrinology. 2021 Jun 15:1-2.

[83] Rubin VR, Bojanic K, Smolic M, Rubin J, Tabll A, Smolic R. An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents. Journal of Clinical and Translational Hepatology. 2021 Feb 28;9(1):60.

[84] Fatouros IG, Mitrakou A. 13 Obesity and Diabetes. Obesity: Prevention and Treatment. 2012 May 11:249.

[85] Kim KS, Lee BW. Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. Clinical and Molecular Hepatology. 2020 Oct;26(4):430.

[86] Lee MH, Wong C, Ng CH, Yuen DC, Lim AY, Khoo CM. Effects of hyperglycaemia on complications of COVID-19: a meta-analysis of observational studies. Diabetes, Obesity and Metabolism. 2021 Jan;23(1):287-9.

[87] Cohen CC, Castillo-Leon E, Farris AB, Caltharp SA, Cleeton RL, Sinclair EM, Shevell DE, Karsdal MA, Nielsen MJ, Leeming DJ, Vos MB. PRO-C3, a Serological Marker of Fibrosis, During Childhood and Correlations With Fibrosis in Pediatric NAFLD. Hepatology Communications. 2021 Jul 8.

[88] Konstantinou F. The Place of GLP-1 Receptor Agonists in the Treatment of NAFLD: A Review. Annal Cas Rep Rev: ACRR-214. 2021.

[89] Mantovani A, Byrne CD, Scorletti E, Mantzoros CS, Targher G. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes & metabolism. 2020 Nov 1;46(6):427-41.

[90] Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang DQ, Portincasa P. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?. International Journal of Molecular Sciences. 2021 Jan;22(10):5375.

[91] Roskilly A, Hicks A, Taylor EJ, Jones R, Parker R, Rowe IA.

Fibrosis progression rate in a systematic review of placebo-treated nonalcoholic steatohepatitis. Liver International. 2021 May;41(5):982-95.

[92] Alzaid A, Schlaeger C, Hinzmann R. 6th annual symposium on self-monitoring of blood glucose (SMBG) applications and beyond, April 25–27, 2013, Riga, Latvia.

[93] Verbeek J, Cassiman D, Lannoo M, Laleman W, Van der Merwe S, Verslype C, Van Steenbergen W, Nevens F. Treatment of non-alcoholic fatty liver disease: can we already face the epidemic?. Acta gastro-enterologica Belgica. 2013 Apr;76(2):200-9.

[94] Karkucinska-Wieckowska A, Simoes IC, Kalinowski P, Lebiedzinska-Arciczewska M, Zieniewicz K, Milkiewicz P, Górska-Ponikowska M, Pinton P, Malik AN, Krawczyk M, Oliveira PJ. Mitochondria, oxidative stress and Non-Alcoholic Fatty Liver Disease: a complex relationship. European Journal of Clinical Investigation. 2021 May 29:e13622.

[95] Zarei M, Aguilar-Recarte D, Palomer X, Vázquez-Carrera M. Revealing the role of peroxisome proliferator-activated receptor β/δ in nonalcoholic fatty liver disease. Metabolism. 2021 Jan 1;114:154342.

[96] Fougerat A, Montagner A, Loiseau N, Guillou H, Wahli W. Peroxisome proliferator-activated receptors and their novel ligands as candidates for the treatment of non-alcoholic fatty liver disease. Cells. 2020 Jul;9(7):1638.

[97] Mello T, Materozzi M, Galli A. PPARs and mitochondrial metabolism: from NAFLD to HCC. PPAR research. 2016 Oct;2016.

[98] Allen JN. The Non-Alcoholic Steatohepatitis Spectrum and Associated Metabolic Risk Factors: The Effects of Impaired Ron Receptor Signaling in Diet-Induced Apolipoprotein E-Deficient Murine Models. The Pennsylvania State University; 2018.

[99] Silva AK, Peixoto CA. Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation. Cellular and Molecular Life Sciences. 2018 Aug;75(16):2951-61.

[100] Negri, R., Trinchese, G., Carbone, F., Caprio, M.G., Stanzione, G., di Scala, C., Micillo, T., Perna, F., Tarotto, L., Gelzo, M. and Cavaliere, G., 2020. Randomised clinical trial: calorie restriction regimen with tomato juice supplementation ameliorates oxidative stress and preserves a proper immune surveillance modulating mitochondrial

bioenergetics of T-lymphocytes in obese children affected by non-alcoholic fatty liver disease (NAFLD). *Journal of clinical medicine*, *9*(1), p.141.

[101] Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Lonardo A. The role of nuclear receptors in the pathophysiology, natural course, and drug treatment of NAFLD in humans. Advances in therapy. 2016 Mar 1;33(3):291-319.

[102] Behr AC, Plinsch C, Braeuning A, Buhrke T. Activation of human nuclear receptors by perfluoroalkylated substances (PFAS). Toxicology in Vitro. 2020 Feb 1;62:104700.

[103] Wu J, Nagy LE, Liangpunsakul S, Wang L. Non-coding RNA crosstalk with nuclear receptors in liver disease. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2021 May 1;1867(5):166083.

[104] Strosznajder AK, Wójtowicz S, Jeżyna MJ, Sun GY, Strosznajder JB. Recent Insights on the Role of PPAR-β/δ in Neuroinflammation and Neurodegeneration, and Its Potential Target for Therapy. NeuroMolecular Medicine. 2021 Mar;23(1):86-98.